Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 2, Pages 1481-1504Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01163
Keywords
-
Categories
Funding
- Medical Research Council [MR/K501402/1]
Ask authors/readers for more resources
This study describes a structure-guided approach to design a selective FGFR2 inhibitor, resulting in a nanomolar potency inhibitor with moderate selectivity for FGFR2. The study reveals that inhibitor-specific morphological differences may play a crucial role in selectivity.
Fibroblast growth factor receptors (FGFRs) are implicated in a range of cancers with several pan-kinase and selective-FGFR inhibitors currently being evaluated in clinical trials. Pan-FGFR inhibitors often cause toxic side effects and few examples of subtype-selective inhibitors exist. Herein, we describe a structure-guided approach toward the development of a selective FGFR2 inhibitor. De novo design was carried out on an existing fragment series to yield compounds predicted to improve potency against the FGFRs. Subsequent iterative rounds of synthesis and biological evaluation led to an inhibitor with nanomolar potency that exhibited moderate selectivity for FGFR2 over FGFR1/3. Subtle changes to the lead inhibitor resulted in a complete loss of selectivity for FGFR2. X-ray crystallographic studies revealed inhibitor-specific morphological differences in the P-loop which were posited to be fundamental to the selectivity of these compounds. Additional docking studies have predicted an FGFR2-selective H-bond which could be utilized to design more selective FGFR2 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available